Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France.
Bregman B, Teitsson S, Orsini I, Cotté FE, Amadi A, Moshyk A, Roze S, Gaudin AF. Bregman B, et al. Among authors: amadi a. Dermatol Ther (Heidelb). 2020 Dec;10(6):1331-1343. doi: 10.1007/s13555-020-00446-z. Epub 2020 Sep 13. Dermatol Ther (Heidelb). 2020. PMID: 32920709 Free PMC article.
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V, Kurt M, Zhang L, Butler MO, Michielin O, Amadi A, Hernlund E, Johnson HM, Kotapati S, Moshyk A, Borrill J. Federico Paly V, et al. Among authors: amadi a. MDM Policy Pract. 2022 Mar 26;7(1):23814683221089659. doi: 10.1177/23814683221089659. eCollection 2022 Jan-Jun. MDM Policy Pract. 2022. PMID: 35356551 Free PMC article.
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, Roskell N, Meng Y. Lee D, et al. Among authors: amadi a. Pharmacoecon Open. 2019 Mar;3(1):43-54. doi: 10.1007/s41669-018-0080-5. Pharmacoecon Open. 2019. PMID: 29790020 Free PMC article.
Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, Roskell N, Meng Y. Lee D, et al. Among authors: amadi a. Pharmacoecon Open. 2019 Mar;3(1):127. doi: 10.1007/s41669-018-0096-x. Pharmacoecon Open. 2019. PMID: 30206825 Free PMC article.
From trench fever to endocarditis.
Mann P, Nye F, Williams G, Walker A, Amadi A. Mann P, et al. Among authors: amadi a. Postgrad Med J. 2003 Nov;79(937):655-6. doi: 10.1136/pmj.79.937.655. Postgrad Med J. 2003. PMID: 14654579 Free PMC article.
89 results